AliveX Biotech Secures Tens of Millions of RMB in Angel Funding to Advance AI-Driven Systems Immunology Platform

VCBeat (WeChat ID: vcbeat) has learned that AliveX Biotech announced the completion of its angel financing round, raising tens of millions of yuan. The round was led by 5Y Capital (formerly Morningside Venture Capital), with Xinyuan Capital participating as a co-investor. The funds will primarily be used to advance the development of its existing product pipeline, continuously optimize its AI-driven systemic immunology technology platform, and further expand industry-academia-research collaborations both domestically and internationally.

AliveX Biotech, established in January 2019, is China’s first innovative biotechnology company to apply AI-enabled systems immunology to clinical practice. Driven by its AI-powered systems immunology technology platform, the company independently develops multi-omics diagnostic products and precision diagnosis and treatment solutions tailored to diverse clinical scenarios, while providing pharmaceutical companies with biomarker-driven new drug development services.

AliveX Biotech boasts robust technical capabilities and strong resource integration abilities. Its professional advisory and expert team comprises academicians in the fields of immunology and oncology from both China and abroad, presidents of top-tier (Grade A tertiary) hospitals, and senior clinical experts across various specialties. The core team consists of cross-disciplinary talents from home and overseas, specializing in immunology, systems biology, clinical medicine, bioinformatics, and artificial intelligence. The scientific team hails from prestigious institutions such as the University of Cambridge, Harvard University, the Chinese Academy of Sciences, and renowned Grade A tertiary hospitals, with prior experience serving international pharmaceutical giants including Roche, AstraZeneca, and Bayer. The AI and bioinformatics teams originate from Intel AI and the Biomedical Big Data Center at the Chinese Academy of Sciences’ Institute of Biology, bringing extensive expertise in omics technologies, biological data analysis, artificial intelligence, and data mining. Following the completion of this funding round, AliveX Biotech will continue to recruit senior international technical experts to build a globally leading R&D platform.

“AliveX Biotech is leveraging its leading AI-driven systems immunology technology to decode the immune system. By adopting a deeply integrated R&D model that combines industry, academia, and research, and by analyzing multi-omics data, the company is fundamentally enhancing the understanding of the human immune system and diseases, thereby creating significant value for the future development of precision medicine,” said Wen Wen, Founder and CEO of AliveX Biotech. “We are deeply grateful to Five Source Capital and Xinyuan Capital for their trust and support in our company. We share a common vision and confidence with our investors regarding the broad application prospects of artificial intelligence and immunology in life sciences. It is a great honor to join hands in shaping the future of life sciences. With this round of financing, the company is confident in establishing an international leading position in the field of AI-driven systems immunology, thereby advancing the R&D of next-generation precision medicine.”

Jing Xutian, Managing Director at Source Code Capital, stated, “The immune system serves as the body’s defense mechanism and is a critical hub influencing the onset, progression, and recovery of human diseases. Prior to the convergence of systems immunology and machine learning, efforts to achieve breakthroughs in disease diagnosis and treatment often focused on single or limited biomarkers. However, given the immense complexity of the immune system—where a slight change can have widespread effects—many diseases cannot be clearly diagnosed or monitored for treatment response through single biomarkers alone. This is precisely where machine learning modeling excels, particularly in handling complex, multi-omics, and multivariate analyses. With the accumulation of multidimensional data in China and the deepening integration of machine learning with immunology, we now have the potential to establish an immune system baseline specific to Asian populations, thereby enhancing disease diagnosis, therapeutic efficacy assessment, and the development of precision medicines. Admittedly, this industry is still in its early stages. At this phase, we prioritize two key capabilities in teams: the ability to efficiently acquire high-quality, multidimensional clinical data, and a profound understanding of systems immunology coupled with strong machine learning algorithm development skills. AliveX Biotech aligns perfectly with our expectations for such a team, and we look forward to collaborating with them to explore the next generation of precision diagnosis and treatment empowered by AI and systems immunology.”

Hua Xue, Partner at HeartYuan Capital, stated: “AliveX Biotech leverages AI to empower systems immunology, constructing a human immune knowledge graph library that guides precise clinical diagnosis and treatment. This approach enables a deeper understanding of the relationship between the human immune system and diseases, uncovers intrinsic disease correlations and potential biomarkers, and advances disease screening and diagnosis and treatment while accelerating the R&D of new drugs and diagnostic methods. The integration of ‘AI + Systems Immunology’ requires a team with strong interdisciplinary capabilities, as well as close collaboration and continuous iteration. AliveX is precisely such a team. HeartYuan Capital is optimistic about the future potential of the AliveX team in translating AI + immunomics technologies into clinical applications. Having established a tightly connected global venture capital community, HeartYuan has become one of the most critical support platforms for entrepreneurs. We look forward to continuing our support for AliveX Biotech as it grows into an internationally leading, global, innovative technology company.”

With the continuous advancement of life sciences, the importance of the human immune system has become increasingly prominent. Research indicates that many diseases threatening human health are closely linked to immunity. In recent years, major pharmaceutical companies, clinical medical communities, and research institutions worldwide have been exploring new solutions for tumors, autoimmune diseases, infectious diseases, neurological disorders, and other conditions from an immunological perspective.

However, the immune system and its interplay with disease are highly complex. Taking malignant tumors as an example, the emergence of immunotherapy has provided physicians and patients with more options. Yet, due to the heterogeneity of both tumors and individual patients, determining the most effective treatment regimen for each patient has become the greatest challenge currently facing cancer immunotherapy. AliveX Biotech is attempting to integrate multi-omics data to elucidate the mechanisms underlying human immune system function, explore the correlations and mechanistic roles of immunity in disease and treatment, and thereby provide a critical foundation and novel insights for next-generation precision diagnostics and therapeutic strategies.

AliveX Biotech has innovatively developed a globally leading AI + Systems Immunology technology platform by integrating artificial intelligence with systems immunology, a field characterized by exceptionally high professional barriers.

Specifically, AliveX Biotech leverages multi-dimensional data—including public databases, literature mining, proprietary clinical immunology data, and data from its multi-omics experimental platforms—to construct a human immune knowledge graph and a big data platform. The latter aggregates large-cohort multi-omics immunological data, encompassing information on interactions and network regulation among cells, genes, and proteins, tailored to address diverse clinical questions. Subsequently, its built-in machine learning algorithms analyze and predict the interaction and operational status of patients' immune systems, as well as their systemic responses to diseases and drugs. This process enables the identification of intrinsic correlations and biomarkers within the "human-disease-drug" axis, thereby facilitating in-depth research and development along with experimental validation.

At this stage, AliveX Biotech primarily leverages its platform technology advantages to collaborate with Grade A tertiary hospitals through scientific research initiatives. By partnering with authoritative clinical experts to address specific clinical pain points, the company has established a deep industry-academia-research collaboration mechanism. This approach facilitates the commercial translation of high-quality research outcomes, forming an R&D model that integrates basic research, applied research, and technological innovation. Currently, AliveX Biotech has established in-depth cooperative relationships with 30 leading domestic and international research institutions, including the Chinese PLA General Hospital, China-Japan Friendship Hospital, West China Hospital of Sichuan University, the First Affiliated Hospital of Zhengzhou University, the University of Oxford, Tsinghua University, and Shanghai Jiao Tong University. The company has accumulated tens of thousands of clinical immunology data sets across various disease areas.

Wen Wen pointed out that, with the scale effects generated by increasing data collection and modeling, AliveX Biotech’s “AI + Systemic Immunity” technology platform will continuously accelerate the development of new diagnostic and therapeutic solutions, ultimately significantly improving the success rate of new drug development and enhancing the efficiency of clinical diagnosis and treatment decision-making.

Currently, AliveX Biotech is progressively building a diagnostic product portfolio based on its “AI + Systems Immunology” technology platform, while continuously expanding collaborative projects with pharmaceutical companies. In the area of diagnostic products, AliveX Biotech has established more than ten R&D pipelines focused on early diagnosis, treatment and efficacy evaluation, and prediction of toxic side effects for diseases such as cancer. Multiple multicenter clinical validations are underway, and diagnostic products are expected to enter the regulatory submission process next year. Regarding collaborations with pharmaceutical companies, AliveX Biotech is engaged in joint research and development with several biotechnology firms both domestically and internationally, primarily focusing on Phase I and II clinical studies of immunotherapeutic drugs.

5Y Capital (formerly Morningside Venture Capital) is one of China’s earliest institutions engaged in early-stage venture capital. It currently manages dual-currency funds in both USD and RMB, with assets under management totaling several billion dollars. Its limited partners include internationally renowned sovereign wealth funds, family offices, funds of funds, and university endowments. 5Y Capital seeks out, supports, and empowers solitary entrepreneurs, providing them with comprehensive assistance ranging from emotional support to operational guidance. We believe that if the “crazy” individuals in others’ eyes begin to gain trust and recognition, the world will become a better place.

Invested companies include Ctrip (NASDAQ:CTRP), JOYY Inc. (NASDAQ:YY), Xiaomi Corporation (HK:01810), Kingsoft Office (STAR Market: 688111), Agora, Inc. (NASDAQ:API), XPeng Inc. (NYSE:XPEV), Kuaishou, WeDoctor Group, SenseTime, Pony.ai, and others.

Xinyuan Capital, established in 2014, is one of the few institutional angel venture capital firms actively operating in both the Chinese and U.S. innovation markets. Focused on investing in angel- and seed-stage startups, Xinyuan empowers bold dreams to become forces that change the world. With teams spanning Taipei, Beijing, and San Francisco, the firm manages nearly $300 million in assets and has invested in companies across Silicon Valley and Greater China. By connecting nearly 200 portfolio companies with over 500 founders, entrepreneurial advisors, and VC investors, Xinyuan has built a tight-knit global community, becoming one of the most critical support platforms for entrepreneurs. It helps them grow their businesses by combining international perspectives with deep local market insights.

Representative projects include the U.S. online healthcare platform “hims & hers,” the meditation and relaxation app “Calm,” “Flexport,” which is driving global logistics industry innovation through technology, the online learning platform “Liulishuo,” China’s pioneer in community group buying “Shixianghui,” Asia’s leading design e-commerce platform “Pinkoi,” and “91APP,” which promotes the integration of online and offline retail.